Similarly, inhibition of the AIM2 inflammasome offers potential for AF risk reduction, with preliminary studies in murine models demonstrating significant decreases in inflammatory burden following treatment with AIM2-antagonizing synthetic oligonucleotides [98]. The gene discussed is AIM2; the disease is atrial fibrillation.